Loading stock data…
$3.80+0.22 (+6.15%)
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
Verrica Pharmaceuticals Inc. in the Healthcare sector is trading at $3.80 with a market capitalization of $79M. Wall Street consensus targets $13.83 (6 analysts), implying a +264.0% move over the next 12 months. The stock is currently near its 52-week low of $3.28, remaining 35.5% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $5.86M↑ | $5.02M↓ | $5.09M↓ | $14.34M↑ | $12.70M |
| Gross Profit | $4.98M↑ | $4.13M↑ | $3.69M↓ | $13.23M↑ | $12.21M |
| Operating Income | -$11.40M↓ | -$9.71M↓ | -$6.95M↓ | $1.63M↑ | $1.51M |
| Net Income | -$13.15M↓ | -$9.68M↓ | -$8.07M↓ | -$274,000↓ | $204,000 |
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combin...